๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Advanced HR+/HER2- Breast Cancer

ABCSG 61 / TEODOR : Neoadjuvant TrEatment Optimization Driven by Circulating Tumor DNA and endOcrine Responsiveness NCT07084558NA14 sites๐Ÿ“ Vienna๐Ÿ“ Baden๐Ÿ“ Dornbirn Austrian Breast & Colorectal Cancer Study Group ยท Tests: blood sample for Signatera (TM) test, biopsy for Ki-67 assessment, FFPE tumor sample for Signatera (TM) test (archived) A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors NCT07318805Phase 113 sites๐Ÿ“ Duarte๐Ÿ“ Grand Rapids๐Ÿ“ Long Island City Pfizer ยท Tests: PF-08032562, Fulvestrant, Cetuximab, Fluorouracil, Oxaliplatin Study of AVZO-021 in Patients With Advanced Solid Tumors NCT05867251Phase 1, Phase 213 sites๐Ÿ“ New Haven๐Ÿ“ Sarasota๐Ÿ“ Tampa Avenzo Therapeutics, Inc. ยท Tests: AVZO-021, Palbociclib, Fulvestrant, Letrozole, Ribociclib HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan NCT06236269Phase 210 sites๐Ÿ“ Badalona๐Ÿ“ L'Hospitalet de Llobregat๐Ÿ“ Barcelona SOLTI Breast Cancer Research Group ยท Tests: Sacituzumab Govitecan A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy NCT07071337Phase 32 sites๐Ÿ“ Beijing๐Ÿ“ Guangzhou Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ยท Tests: SKB264, Nab-paclitaxel, Paclitaxel, Capecitabine Radiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC. NCT06705127Phase 21 site๐Ÿ“ Hangzhou First Affiliated Hospital of Zhejiang University ยท Tests: TORIPALIMAB INJECTION(JS001 ), Stereotactic Body Radiation Therapy (SBRT) A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03) NCT07648914Phase 31 site๐Ÿ“ Beijing Sichuan Baili Pharmaceutical Co., Ltd. ยท Tests: BL-B01D1, Albumin-Bound Paclitaxel, Paclitaxel, Capecitabine Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors NCT07288359Phase 1, Phase 216 sites๐Ÿ“ Atlanta๐Ÿ“ Nashville๐Ÿ“ San Antonio Novartis Pharmaceuticals ยท Tests: GVV858, Fulvestrant, Letrozole Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer NCT05949541Phase 21 site๐Ÿ“ Shanghai Fudan University ยท Tests: Everolimus 10 mg, CDK4/6 Inhibitor SHR6390, Aromatase inhibitor and Fulvestrant combined with CDK4/6 inhibitors Dalpiciclib Plus Toremifene for First-line Advanced HR Positive and HER2 Negative Breast Cancer NCT06495515Phase 21 site๐Ÿ“ Tianjin Tianjin Medical University Cancer Institute and Hospital ยท Tests: Dalpiciclib๏ผŒToremifen Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors NCT05969041Phase 16 sites๐Ÿ“ Darlinghurst๐Ÿ“ Randwick๐Ÿ“ Westmead Myeloid Therapeutics ยท Tests: MT-302 (A) Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study NCT06805812n/a24 sites๐Ÿ“ Aviano๐Ÿ“ Brescia๐Ÿ“ Catania Fondazione IRCCS Istituto Nazionale dei Tumori, Milano ยท Tests: Palbociclib, Ribociclib, Abemaciclib A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. NCT07062965Phase 3433 sites๐Ÿ“ Anchorage๐Ÿ“ Chandler๐Ÿ“ Gilbert Pfizer ยท Tests: PF-07248144, Fulvestrant, Everolimus, Exemestane A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors NCT07383506Phase 112 sites๐Ÿ“ Scottsdale๐Ÿ“ Los Angeles๐Ÿ“ Palo Alto Cogent Biosciences, Inc. ยท Tests: CGT6297 Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer. NCT07227233Phase 21 site๐Ÿ“ La Jolla University of California, San Diego ยท Tests: A CDK4/6 inhibitor different from the first that the participant had received, plus fulvestrant., Treatment of physiciaโ€ฆ Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors NCT05985655Phase 1, Phase 215 sites๐Ÿ“ Los Angeles๐Ÿ“ Grand Rapids๐Ÿ“ New York Exscientia AI Ltd., a wholly owned subsidiary of Recursion โ€ฆ ยท Tests: GTAEXS617, SoC A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer NCT05851014Phase 352 sites๐Ÿ“ Bengbu๐Ÿ“ Hefei๐Ÿ“ Hefei Genor Biopharma Co., Ltd. ยท Tests: GB491 combined with Letrozole, Placebo combined with Letrozole Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer NCT06982521Phase 3243 sites๐Ÿ“ Gilbert๐Ÿ“ Beverly Hills๐Ÿ“ Duarte Relay Therapeutics, Inc. ยท Tests: Zovegalisib, Capivasertib, Fulvestrant Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase โ…ก Clinical Trial NCT06176534Phase 21 site๐Ÿ“ Zhengzhou Henan Cancer Hospital ยท Tests: Experimental: chemotheyapy, Active Comparator: endocrine therapy Neoadjuvant SNF Precision Therapy Phase III NCT06913777Phase 31 site๐Ÿ“ Shanghai Fudan University ยท Tests: Targeted therapy agents: SNF2 -adebrelimab + famitinib; SNF3 -fluzoparib; SNF4 -apatinib, Chemotherapy (wP-EC) SNF Platform Study of HR+/ HER2-advanced Breast Cancer NCT05594095Phase 21 site๐Ÿ“ Shanghai Fudan University ยท Tests: PIK3CA inhibitor, AKT inhibitor, Carrelizumab, Famitinib, Fluzoparib Current Status of Treatment for Chinese Patients With ESR1-mutated HR+/HER2-advanced Breast Cancer NCT06548919n/a1 site๐Ÿ“ Suzhou SciClone Pharmaceuticals ยท Tests: Endocrine therapy, Chemotherapy Prednisone A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC NCT06439771Phase 21 site๐Ÿ“ Shanghai MediLink Therapeutics (Suzhou) Co., Ltd. ยท Tests: YL202 should be intravenously infused A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations NCT07109726Phase 1, Phase 220 sites๐Ÿ“ Duarte๐Ÿ“ Irvine๐Ÿ“ Orlando Terremoto Biosciences Inc. ยท Tests: TER-2013, Fulvestrant injection A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors NCT06827613Phase 1, Phase 28 sites๐Ÿ“ Los Angeles๐Ÿ“ Los Angeles๐Ÿ“ Boston Marengo Therapeutics, Inc. ยท Tests: STAR0602, Sacituzumab Govitecan (SG) A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors NCT07767474Phase 1, Phase 26 sites๐Ÿ“ Fort Worth๐Ÿ“ Houston๐Ÿ“ San Antonio Antares Therapeutics, Inc ยท Tests: ATX-898, ATX-898, ATX-898, ATX-898, ATX-898 FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer NCT05304962Phase 18 sites๐Ÿ“ La Jolla๐Ÿ“ Los Angeles๐Ÿ“ Port Saint Lucie Regor Pharmaceuticals Inc. ยท Tests: RGT-419B, RGT-419B in combination with hormonal therapy Sapu003 in Advanced mTOR-sensitive Solid Tumors NCT07369505Phase 11 site๐Ÿ“ Adelaide SAPU NANO (US) LLC ยท Tests: Sapu003, Exemestane 25 MG A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor NCT07612891Phase 1, Phase 21 site๐Ÿ“ Shanghai Shenzhen Ionova Life Sciences Co., Ltd. ยท Tests: INV-6452 A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) NCT06312176Phase 3259 sites๐Ÿ“ Chandler๐Ÿ“ Gilbert๐Ÿ“ Fullerton Merck Sharp & Dohme LLC ยท Tests: Sacituzumab tirumotecan, Pembrolizumab, Paclitaxel, Nab-paclitaxel, Capecitabine
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy